The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, comments on the lack of therapeutic application of checkpoint inhibitors for the treatment of pancreatic cancer. Despite this, Dr Alese suggests that advances in understanding the immune microenvironment of patients with pancreatic cancer may eventually enable the development of effective immunotherapies that utilize immune checkpoint inhibitors. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
